• 1
    Janssen-Heijnen ML, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer 2007; 43: 217993.
  • 2
    Iversen LH, Norgaard M, Jacobsen J, et al. The impact of comorbidity on survival of Danish colorectal cancer patients from 1995 to 2006—a population-based cohort study. Dis Colon Rectum 2009; 52: 718.
  • 3
    Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 2000; 356: 96874.
  • 4
    Gross CP, Guo Z, McAvay GJ, et al. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 2006; 54: 1898904.
  • 5 Accessed on May 5, 2012.
  • 6
    Vestal RE. Aging and pharmacology. Cancer 1997; 80: 130210.
  • 7
    Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22: 3099103.
  • 8
    Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005; 55: 23140.
  • 9
    Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 24417.
  • 10
    van de Schans SA, Janssen-Heijnen ML, Biesma B, et al. COPD in cancer patients: higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patient. Eur J Cancer 2007; 43: 2194202.
  • 11
    Janssen-Heijnen ML, Szerencsi K, van de Schans SA, et al. Cancer patients with cardiovascular disease have survival rates comparable to cancer patients within the age-cohort of 10 years older without cardiovascular morbidity. Crit Rev Oncol Hematol 2010; 76: 196207.
  • 12
    Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67: 12432.
  • 13
    Frederiksen BL, Osler M, Harling H, et al. The impact of socioeconomic factors on 30-day mortality following elective colorectal cancer surgery: a nationwide study. Eur J Cancer 2009; 45: 124856.
  • 14
    Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010; 28: 408693.
  • 15
    Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. JAMA 2010; 303: 13034.
  • 16
    Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997; 80: 127383.
  • 17
    Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Age and co-morbidity in cancer patients: a population-based approach. Cancer Treat Res 2005; 124: 89107.
  • 18
    Schouten LJ, Jager JJ, van den Brandt PA. Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer 1993; 68: 9747.
  • 19
    De Marco MF, Janssen-Heijnen ML, van der Heijden LH, et al. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000; 36: 959.
  • 20
    Coebergh JW, Janssen-Heijnen ML, Post PN, et al. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993–1996. J Clin Epidemiol 1999; 52: 11316.
  • 21
    Houterman S, Verheij CDGW, Janssen-Heijnen MLG, et al. Validation study on co-morbidity in colorectal cancer patients diagnosed between 1995 and 1999. Eindhoven Cancer Registry, Internal report, Eindhoven, 2001.
  • 22
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 37383.
  • 23
    Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008; 14 (Suppl 1): 2832.
  • 24
    Tacken MA, Opstelten W, Vossen I, et al. Increased multimorbidity in patients in general practice in the period 2003–2009. Ned Tijdschr Geneeskd 2011; 155: A3109.
  • 25
    Schers H, Bor H, van den Hoogen H, et al. What went and what came? Morbidity trends in general practice from the Netherlands. Eur J Gen Pract 2008; 14 (Suppl 1): 1324.
  • 26 G. E. Nagelhout Report. Trendpublicatie percentage rokers. Percentage rokers in de Nederlandse bevolking. 1958–2011, Den Haag: Stivoro. Accessed on May 5, 2012.
  • 27
    Banos G, Guarner V, Perez-Torres I. Sex steroid hormones, cardiovascular diseases and the metabolic syndrome. Cardiovasc Hematol Agents Med Chem 2011; 9: 13746.
  • 28
    Silbiger S, Neugarten J. Gender and human chronic renal disease. Gend Med 2008; 5 (Suppl A): S3S10.
  • 29
    Louwman WJ, Aarts MJ, Houterman S, et al. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 2010; 103: 17428.
  • 30
    Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012; 380: 3743.
  • 31
    Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol 2008; 26: 25327.
  • 32
    Lemmens VE, Janssen-Heijnen ML, Houterman S, et al. Which comorbid conditions predict complications after surgery for colorectal cancer? World J Surg 2007; 31: 1929.
  • 33
    Lemmens VE, Janssen-Heijnen ML, Verheij CD, et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005; 92: 61523.
  • 34
    Fazio VW, Tekkis PP, Remzi F, et al. Assessment of operative risk in colorectal cancer surgery: the Cleveland Clinic Foundation colorectal cancer model. Dis Colon Rectum 2004; 47: 201524.
  • 35
    Longo WE, Virgo KS, Johnson FE, et al. Risk factors for morbidity and mortality after colectomy for colon cancer. Dis Colon Rectum 2000; 43: 8391.
  • 36
    Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005; 294: 71624.
  • 37
    Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 20617.